Immunotherapy for the Treatment of Triple-Negative Breast Cancer
Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®
From Dana-Farber Cancer Institute, Boston, Massachusetts
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2022;13(3):298–301 |
© 2022 Harborside™
At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast cancer. Dr. Tolaney and Ms. Shaw also discussed principles of monitoring and managing adverse events associated with immunotherapies.
For access to the full length article, please sign in